The Role of Novel Bone Forming Agents in the Treatment of Osteoporosis

• Published in: Journal of Pharmacy Practice 2021-12, Vol.34 (6), p.952-961
• Main Authors: Patel, Hansita B., Lyerly, Lynsie J., Horlen, Cheryl K.
• Format: Article
• Language: English
• ISSN: 0897-1900; 1531-1937
• DOI: 10.1177/0897190020961227

Osteoporosis is a growing epidemic that leads to significant morbidity and mortality among the elderly population due to associated fractures that lead to disabilities and reduced quality of life. Bisphosphonates are well-established as a first-line and cost-effective treatment for osteoporosis. Unfortunately, clinicians are often uncertain as to how to select treatments when bisphosphonates are ineffective as initial treatment or contraindicated. Romosozumab and abaloparatide are 2 alternative agents that have been recently FDA approved for the treatment of osteoporosis in postmenopausal women at high risk for fracture or patients who have failed or are intolerant to other osteoporosis therapies. Currently, the National Osteoporosis Foundation (NOF) has no formal recommendations in regard to these 2 novel agents. The purpose of this review is to help guide pharmacists on how to ensure appropriate utilization of these 2 novel bone-forming agents as potential alternatives to bisphosphonate therapy by providing evidence-based recommendations according to the current literature and key counseling points.